Disclosures: Tae-Hwi Schwantes-An: Target RWE: Consultant, Eduardo Vilar-Gomez: Nothing to Disclose, Marco Abreu: Nothing to Disclose, Brent Neuschwander-Tetri: Akero: Consultant, Aligos: Consultant, Arrowhead: Consultant, Corcept: Consultant, GSK: Consultant, Hepion: Consultant, HIstoIndex: Consultant, Madrigal: Consultant, Madrigal: Grant/Research Support, Merck: Consultant, Mirum: Consultant, Sagimet: Consultant, Senseion: Consultant, HepGene: Stock privately held company, HeptaBio: Stock privately held company, Miriam Vos: Nothing to Disclose, Jian Wang: Nothing to Disclose, Xiuqing Guo: Nothing to Disclose, Jingyi Tan: Nothing to Disclose, Robert A Hegele: Nothing to Disclose, Nicholas Davidson: Nothing to Disclose, George Hindy: Regeneron Pharmaceuticals: Employee, Luca Lotta: Nothing to Disclose, Niek Verweij: Nothing to Disclose, Jerome Rotter: Nothing to Disclose, Naga Chalasani: Madrigal: Consultant, Zydus, Ipsen, Pfizer, Merck, Altimmune, GSK: Consultant, Exact Sciences: Grant/Research Support, NIH: Grant/Research Support 2567 EXPLORING THE PROTECTIVE ROLE OF LYPLAL1 LOSS-OF-FUNCTION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Rawdat Hussain 1 Chinmay Raut 1 Prabhu Ponnandy 1 Akram Irshaid 1 Brian Halligan 2 Elizabeth Speliotes 2 , 1 University of Michigan, 2 University of Michigan Medical Center Background: Human genetics studies have linked single-nucleotide polymorphisms near LYPLAL1 with metabolic dysfunction-associated steatotic liver disease (MASLD)
*This website, including products, articles, and educational content are not intended to diagnose, cure, or prevent any disease
& Montestruque, S
It's why users often report better results from the combination than from any peptide used alone
C.RibasF
The Importance of Purity and Transparency When choosing how to support your wellness, the quality of your sources matters as much as the ingredients themselves
